In this study, we aimed to overcome the limitations of existing CCA treatments by studying AZGP1 as a novel therapeutic target or diagnostic biomarker in CCA and demonstrated that AZGP1 acts as a tumour suppressor in CCA. The gene discussed is AZGP1; the disease is neoplasm.